Transcode Therapeutics, Inc. — Investor Relations & Filings
Transcode Therapeutics, Inc. is a clinical-stage oncology company developing RNA-based therapeutics for metastatic cancer. The company's strategy focuses on the specific eradication of metastatic tumor cells by targeting microRNA-10b (miRNA-10b), identified as a master regulator of metastasis. Its lead therapeutic candidate, TTX-MC138, is an oligonucleotide designed to inhibit miRNA-10b. Transcode utilizes a proprietary iron oxide nanoparticle delivery platform, TTX, to transport its therapeutic candidates to tumor sites. Pre-clinical studies in murine models have demonstrated that TTX-MC138 can induce regression of established metastases in breast and pancreatic cancers. The company's approach has potential applicability across numerous cancer types where miRNA-10b is involved, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-30 | English | |
| 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-07 | English | |
| 8-K - TRANSCODE THERAPEUTICS, INC. (0001829635) (Filer) | 2026-03-03 | English | |
| 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-02-23 | English | |
| 8-K Filing | 2026-02-05 | English | |
| Major Shareholding Notification 2026 | 2026-01-07 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39241455 | S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-30 | English | ||
| 33708775 | 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-04-07 | English | ||
| 32899329 | 8-K - TRANSCODE THERAPEUTICS, INC. (0001829635) (Filer) | 2026-03-03 | English | ||
| 32827319 | 8-K - Transcode Therapeutics, Inc. (0001829635) (Filer) | 2026-02-23 | English | ||
| 31953280 | 8-K Filing | 2026-02-05 | English | ||
| 13329328 | Major Shareholding Notification 2026 | 2026-01-07 | English | ||
| 13329327 | FORM 8-K | 2026-01-06 | English | ||
|
2025
8 filings
| |||||
| 13329329 | DEFA14A | 2025-12-23 | English | ||
| 13329332 | FORM 8-K/A | 2025-12-23 | English | ||
| 13329330 | Regulatory Filings 2025 | 2025-12-23 | English | ||
| 13329331 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13329333 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13329334 | FORM 8-K | 2025-12-22 | English | ||
| 13329335 | S-3 | 2025-12-12 | English | ||
| 13329336 | FORM 8-K | 2025-12-11 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
PegBio Co., Ltd.
Specializes in discovering and developing innovative therap…
|
2565 | HK | Professional, scientific and te… |
|
PELL BIO-MED TECHNOLOGY CO., LTD.
Develops advanced cell and gene therapies, including CAR-T …
|
6949 | TW | Professional, scientific and te… |
|
PepGen Inc.
Develops oligonucleotide therapeutics for neuromuscular and…
|
PEPG | US | Professional, scientific and te… |
|
PERCHERON THERAPEUTICS LIMITED
Clinical-stage developer of antisense pharmaceuticals for r…
|
PER | AU | Professional, scientific and te… |
|
Perseus Proteomics Inc.
Develops antibody-based therapeutics, diagnostics, and rese…
|
4882 | JP | Professional, scientific and te… |
|
PExA AB
Develops non-invasive technology for respiratory medicine b…
|
PEXA B | SE | Professional, scientific and te… |
|
PharmaResources (Shanghai) Co., Ltd.
Integrated CRO and CDMO for small molecule drug discovery a…
|
301230 | CN | Professional, scientific and te… |
|
Pharmaron Beijing Co., Ltd
Delivers integrated R&D and manufacturing across the entire…
|
3759 | HK | Professional, scientific and te… |
|
Pharmaron Beijing Co., Ltd.
Integrated R&D provider for drug discovery, development, an…
|
300759 | CN | Professional, scientific and te… |
|
Pharos iBio Co., Ltd.
Clinical-stage biotech using AI to develop therapies for ra…
|
388870 | KR | Professional, scientific and te… |
Transcode Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35264/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35264 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35264 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35264 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35264}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Transcode Therapeutics, Inc. (id: 35264)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.